



Table of Contents

- [1] Nuclear Forensic Search Project. [Online] <https://metadata.berkeley.edu/nuclear-forensics/Decay%20Chains.html>.
- [2] World nuclear association. [Online] 2016. <https://www.world-nuclear.org/information-library/nuclear-fuel-cycle/mining-of-uranium/world-uranium-mining-production.aspx>.
- [3] Ali, M., Kumar, A., Kumar, M., & Pandey, B. N. (2016). The interaction of human serum albumin with selected lanthanide and actinide ions: Binding affinities, protein unfolding and conformational changes. *Biochimie* 123, 117-129.
- [4] Faa, A., Gerosa, C., Fanni, D., Floris, G., Eyken, P. V., Lachowicx, J. I., & Nurchi, V. M. (2018). Depleted Uranium and Human Health. *Current Medicinal Chemistry*, 49-64.
- [5] Fattal, E., Tsapis, N., & Phan, G. (2015). Novel drug delivery systems for actinides (uranium and plutonium) decontamination. *Advanced Drug Delivery Reviews*, 40-54.
- [6] INES,IAEA,<https://www.iaea.org/resources/databases/international-nuclear-and-radiological-event-scale>
- [7] centers for disease control and prevention. [Online] <https://www.cdc.gov/nceh/radiation/emergencies/moretypes.htm>.
- [8] Versene. (2018, May). *Chelation Chemistry General Concepts of the Chemistry of Chelation.*: Dow chemical company
- [9] Y.-W. Lin. (2020) «Uranyl Binding to Proteins and Structural-Functional Impacts,» *Biomolecules*, vol. 10, p. 457.
- [10] Sigma aldrich safety data sheet apo-transferrin 600 mg lot slcf 2424 product code t1428
- [11] Christian Basset, Olivier Averseng, Pierre-Jean Ferron, Nicolas Richaud, Agnès Hagège, Olivier Pible, and Claude Vidaud, *Chemical Research in Toxicology* 2013 26 (5), 645-653.
- [12] Vidaud, C., & all, e. (2007). Structural Consequences of Binding of UO₂ 2+ to Apotransferrin: Can This Protein Account for Entry of Uranium into Human Cells? *Biochemistry*, 2215-2226.
- [13] K. Haas, «Chelating ligands,» *Saint Mary's College: CHEM 342 Bioinorganic chemistry*, 2020.
- [14] S. J. Flora and V. Pachauri. (2010) «Chelation in Metal Intoxication,» *International journal of environmental research and public health*, vol. 7, pp. 2745-2788.
- [15] Rai , D., Moore, D., Rosso , K., Felmy, A., & Jr., H. (2008). Environmental Mobility of Pu(IV) in the Presence of Ethylenediaminetetraacetic Acid: Myth or Reality? *J Solution Chem*, 957-986.



- [16] X. wang, X. Dai, C. Shi, J. Wan, M. A. Silver, L. Zhang, L. Chen, X. Yi, B. Chen, D. Zhang, K. Yang, J. Diwu, J. Wang, Y. Xu, R. zou, Z. Chai et S. Wang. A 3,2-Hydroxypyridinone-based Decorporation Agent that Removes Uranium from Bones In Vivo. *Nat Commun* **10**, 2570 (2019).
- [17] Abergel, R. (2017). *Chelation of Actinides*.
- [18] Lawrence, G. D., Patel, K. S., Nusbaum, P., & Nusbaum, A. (2014). Uranium toxicity and chelation therapy. *PureAppl.Chem*, 1105-1110.
- [19] Yue, Y.-C., Li, M.-H., Wang, H.-B., Zhang, B.-L., & He, W. (2018). The toxicological mechanisms and detoxification of depleted uranium exposure. *Environmental Health and Preventive Medicine*
- [20] E. Ansoborlo, B. Amekraz, C. Moulin, V. Moulin, F. Taran, T. Bailly, R. Burgada, M.-H. Henge-Napoli, A. Jeanson, C. D. Auwer, L. Bonin et P. Moisy, «Review of actinide decorporation with chelating agents,» *C. R. Chimie (10)*, pp. 1010-1019, 2007
- [21] Rees, J. A., & all, e. (2018). *Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents*
- [22] W. Yantasee, T. Sangvanich, J. A. Creim et K. Pattamakomsan, Functional sorbents for selective capture of plutonium, americium, uranium, and thorium in blood, *Health physics* 99(3), 413-419 2020